MYAMBUTOL (ethambutol hydrochloride) by Bayer is clinical pharmacology ethambutol hcl, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/ml in serum 2 to 4 hours after administration. Approved for pulmonary tuberculosis. First approved in 1967.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
MYAMBUTOL (ethambutol hydrochloride) is an oral small-molecule antimycobacterial agent approved in 1967 for pulmonary tuberculosis. It works by inhibiting metabolite synthesis in actively growing Mycobacterium tuberculosis cells, causing impairment of cell metabolism and arrest of multiplication. The drug achieves peak serum concentrations of 2-5 mcg/mL within 2-4 hours and is primarily renally eliminated with minimal accumulation in patients with normal kidney function.
With lifecycle approaching loss of exclusivity and minimal Part D spending ($10K in 2023), the commercial team is likely small and focused on managed care and international markets rather than growth initiatives.
CLINICAL PHARMACOLOGY ETHAMBUTOL HCL, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/mL in serum 2 to 4 hours after administration. When the drug is administered daily for longer periods of time at this dose, serum levels are similar. The serum level of…
Worked on MYAMBUTOL at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked job openings and approaching loss of exclusivity, MYAMBUTOL offers minimal career growth but provides stable, specialized expertise in infectious disease, compliance, and managed care for professionals in niche pharmaceutical roles. Career advancement would likely require transition to other products or a shift toward global health and TB treatment programs.